Health unicorn Alan raises €480m Series G round led by Prosus
Healthtech startup Alan has raised a €480m Series G funding round, valuing the digital insurer and healthcare platform at €5.5bn. Dutch investment giant Prosus led…
-
-
Two “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Xella Health has launched what it calls the first AI precision health platform built for the XX chromosome. The company says it aims to address…
-
Healthcare Must Avoid Layering AI Tools on a Broken Foundation
The data is stark: A 2025 time-motion study from Vanderbilt University School of Medicine, published in The Journal for Healthcare Quality, found that registered…
-
ONTO Health Acquires LEVY Health to Scale Fertility Care Infrastructure Across the U.S. and GCC
LEVY Co-founders Caroline Mitterdorfer, Silvia Hecher, and Theresa Vilsmaier. Image: LEVY Health ONTO Health, a physician-led fertility and longevity provider, has acquired LEVY Health, a…
-
AdaptHealth discloses patient data was stolen in cyberattack
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. AdaptHealth disclosed last week that a recent…
-
UK Consensus Promotes Intravascular Ultrasound Use – EMJ
INTRAVASCULAR ULTRASOUND is at the centre of a new UK consensus statement that calls for broader adoption during percutaneous coronary intervention. The consensus statement was…
-
Hera Raises $27M to Scale AI-Powered Senior Care Coordination
What You Should Know Senior care coordination pioneer Hera has announced a $27M Series A funding round led by Bain Capital Ventures, with continued backing…
-
Older women face lower chance of fertility treatment working, even with donor eggs, study finds
Most IVF add-ons lack reliable evidence, with benefits either absent or inconclusive, the largest review of its kind has found. More than 70 per cent…
-
Europe’s proactive health startups, mapped
The first wave of the digital health revolution was focused on access. The Covid pandemic accelerated demand for online doctors, prescription delivery, virtual therapy and…
-
FDA Approves Pfizer’s IBRANCE for HR+/HER2+ Metastatic Breast Cancer
The FDA has approved Pfizer‘s IBRANCE (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR+/HER2+ locally…
